

CITATION REPORT

List of articles citing

Regulation of biosimilar medicines and current perspectives on interchangeability and policy

DOI: 10.1007/s00228-018-2542-1

European Journal of Clinical Pharmacology, 2019, 75, 1-11.

Source: <https://exaly.com/paper-pdf/74491739/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
43	Are we ready to close the discussion on the interchangeability of biosimilars?. <i>Drug Discovery Today</i> , 2019 , 24, 1963-1967	8.8	20
42	Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America. <i>Neurology and Therapy</i> , 2019 , 8, 207-214	4.6	4
41	Medication safety risks to be managed in national implementation of automatic substitution of biological medicines: a qualitative study. <i>BMJ Open</i> , 2019 , 9, e032892	3	5
40	Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. <i>British Journal of Ophthalmology</i> , 2020 , 104, 2-7	5.5	17
39	Clinical evidence supporting the marketing authorization of biosimilars in Europe. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 557-566	2.8	5
38	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. <i>Digestive and Liver Disease</i> , 2020 , 52, 138-142	3.3	13
37	Clinical and Regulatory Concerns of Biosimilars: A Review of Literature. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	13
36	Forecasting drug utilization and expenditure: ten years of experience in Stockholm. <i>BMC Health Services Research</i> , 2020 , 20, 410	2.9	5
35	Physicians' perceptions of the uptake of biosimilars: a systematic review. <i>BMJ Open</i> , 2020 , 10, e034183	3	25
34	Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2020 , 183, 397-398	4	8
33	Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea. <i>Applied Health Economics and Health Policy</i> , 2020 , 18, 557-566	3.4	4
32	A health economic guide to market access of biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 9-17	5.4	6
31	Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	3
30	Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice. <i>British Journal of Cancer</i> , 2021 , 124, 1346-1352	8.7	5
29	The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. <i>Advances in Therapy</i> , 2021 , 38, 2077-2093	4.1	4
28	Safety of switching between rituximab biosimilars in onco-hematology. <i>Scientific Reports</i> , 2021 , 11, 5956	4.9	2
27	The global landscape on interchangeability of biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-16	5.4	2

26	Biosimilars: Review of regulatory, manufacturing, analytical aspects and beyond. <i>Microchemical Journal</i> , 2021 , 165, 106143	4.8	5
25	Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 27, 1195-1204	1.7	1
24	Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2021 , 10, 205	3	
23	metabolism of HMTD and blood stability and toxicity of peroxide explosives (TATP and HMTD) in canines and humans. <i>Xenobiotica</i> , 2021 , 51, 394-403	2	3
22	Interchangeability and substitution of biosimilars: is health technology assessment (HTA) a tool for decision-making?. <i>Cadernos De Saude Publica</i> , 2019 , 35, e00087219	3.2	1
21	Community pharmacists' preparedness for substituting biologics and dispensing biosimilars - Lessons learned from a multinational survey.. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021 , 4, 100084		
20	Is the Compulsory Licensing Mechanism Guaranteed by TRIPS the Best Remedy to Improve Access to Biological Therapies Worldwide?. <i>Eastern European Journal of Transnational Relations</i> , 2019 , 3, 39-52		0
19	Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access. <i>Comparative Economic Research</i> , 2020 , 23, 103-115	0.6	0
18	Optimizing Use of Biologic Medicines Using a Quality Use of Medicines Approach. 2020 , 237-251		
17	A Checklist for Pharmacists on Biologics and Biosimilars. 2020 , 267-293		
16	Pharmacoeconomics of Biologic Medicines and Biosimilars. 2020 , 195-212		1
15	Biosimilarity and Interchangeability of Biologic Drugs-General Principles, Biophysical Tests, and Clinical Requirements to Demonstrate Biosimilarity. 2020 , 109-124		
14	Biosimilars: A novel perspective in diabetes therapy. <i>Asian Pacific Journal of Tropical Medicine</i> , 2020 , 13, 288	2.1	
13	Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.. <i>PLoS ONE</i> , 2022 , 17, e0262537	3.7	0
12	An overview of legal and regulatory challenges of biological products. 2022 , 275-286		
11	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging.. <i>Frontiers in Medicine</i> , 2022 , 9, 820755	4.9	1
10	Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?. <i>Patient Related Outcome Measures</i> , 2022 , 13, 79-95	2.9	
9	Pharmacists' Perspectives of Biosimilars: A Systematic Review. <i>BioDrugs</i> , 2022 , 36, 489-508	7.9	1

- 8 Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. **2022**, 10, 2045 ○
- 7 Pharmacovigilance of Biological Drugs. ○
- 6 Malaysian Hospital Pharmacists' Perspectives and Their Role in Promoting Biosimilar Prescribing: A Nationwide Survey. ○
- 5 A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies. **2023**, 113, 108-123 1
- 4 Sulfathiazole treats type 2 diabetes by restoring metabolism through activating CYP19A1. **2023**, 1867, 130303 ○
- 3 How to Become a Successful Hospital and Community Pharmacist. **2023**, 263-287 ○
- 2 Recommendations on TNF α inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance. 1-17 ○
- 1 Emerging Targeted Therapies for HER2-Positive Breast Cancer. **2023**, 15, 1987 ○